WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke QIAGEN - Sample to Outcome wurde als Wortmarke am 09.05.2019 bei der Weltorganisation für geistiges Eigentum angemeldet.
| Markenform | Wortmarke |
| Aktenzeichen | 1480598 |
| Registernummer | 017995107 |
| Länder | 
|
| Basismarke |
Nr. 017995107,
15. Mai 2019
|
| Anmeldedatum | 09. Mai 2019 |
| Ablaufdatum | 09. Mai 2029 |
Markeninhaber
Qiagen Str. 1
40724 Hilden
DE
40724 Hilden
DE
Markenvertreter
Kaiserstraße 100
52134 Herzogenrath
DE
Waren und Dienstleistungen
09
Computer software; computer software and related databases
for use in nucleic acid and protein assay analysis and for
quality control, validation, interpretation, reporting,
clinical decision support, data management, integration with
medical records, physician portals, laboratory networking,
professional healthcare and trial matching services all
related to molecular and genomic analysis; computer
software, namely evidence-based decision support software
used as an aid in the interpretation of variants observed in
genomic sequencing data; computer software for evaluation of
genomic variants in the context of published biomedical
literature, professional association guidelines, publicly
available databases and annotations, drug labels, and/or
clinical-trials; computer software for bioinformatics
analyses, optionally combined with data management,
graphical viewing and output options; computer programs and
software for biological data mining; computer programs and
software for developing bioinformatics database for others;
bio-chips for research or scientific purposes; DNA-chips;
RNA-chips; next-generation sequencing (NGS) data processor;
bioinformatics data processor; online non-downloadable
software for use in bioinformatics, genomics, phenomics,
microbiome, and metagenomics applications; computer hardware
and software for collecting, storing, analyzing,
visualizing, and interpreting bioinformatics, genomics, and
phenomics data sets; computer hardware and software for the
monitoring of pathogens; computer hardware and software for
receiving, processing, transmitting and displaying
associated genomics and phenomics data; computer databases
for bioinformatics, genomics, phenomics, microbiome,
metagenomics, organism-and -pathogen-specific genotype
records, and organism and pathogen-specific phenotype
information; computer software for use in the integration,
analysis and visualization of biomedically relevant
information allowing users to explore compound, target,
assay, biological pathway and disease information; computer
software and databases for the analysis of genomes, exomes,
targeted amplicons, transcriptomes, and epigenetic NGS
sequencing data; computer software, tools, and visualization
modules, for analysis, discovery, verification, and
validation of disease biomarkers
10
Medical diagnostic testing instruments for processing and
analysis of genetic samples primarily for single-cell
genomic, transcriptomic, or proteomic analysis; medical and
diagnostic apparatus for tests, using gene expression tests,
gene expression profiling assays, genetic information and
data, protein biomarkers, clinical data, and/or demographic
information; testing apparatus for medical purposes with
respective use of bioinformatics and machine learning
algorithms and medical data to support treatment decisions;
medical tests apparatus quantifying biomarker levels and
relative expression of host response genes; medical
apparatus and instruments for detecting tumor cancer,
heredity and genetic diseases; testing apparatus for samples
of body fluids, tissue and organ; genome machine for medical
purposes; diagnostic apparatus for the detection of cancer,
genetic or heredity diseases
42
Providing temporary use of online non-downloadable software
for use in bioinformatics, genomics, phenomics, microbiome,
and metagenomics applications; hosting of computer databases
featuring information relating to bioinformatics, genomics,
phenomics, microbiome, metagenomics, organism- and
pathogenspecific genotype records, and organism and
pathogen-specific phenotype information; consulting relating
to computer programming for acquiring, creating, sharing,
managing, mining, analyzing, visualizing, interpreting and
applying genomics and phenomics records; providing
scientific analysis in the field of next generation
sequencing (NGS), namely, the analysis and interpretation of
genomic data obtained from patients; providing an online,
non-downloadable computer software platform for purposes of
storing and providing information about an individual's
disease profile and genomic changes to enable physicians and
healthcare professionals to optimize treatment in clinical
practice; providing temporary use of on-line nondownloadable
software and applications for genome analysis, developing
personal treatment strategies for patients with diagnosed
cancer and other diseases or disorders; conducting early
evaluations in the field of pharmaceuticals; consulting
services in the fields of biotechnology and pharmaceutical
research; providing information about medical and scientific
research in the field of bioinformatics to enable physicians
and healthcare professionals to optimize treatment in
clinical practice; computer programming services for medical
reporting, namely for creating, sharing, managing, mining,
analyzing, visualizing, interpreting and applying genomics
and phenomics records; scientific research services, namely,
providing information relating to research in the field of
specific molecular and genomic sciences for analytical and
clinical purposes, for the treatment of cancer and other
diseases and disorders and for individuals' responses to
drug treatments; providing scientific advice in the fields
of cancer biology, cancer treatment, pharmaceutical side
effects, genomics, cancer medicine and translational
medicine; providing scientific analysis in the field of next
generation sequencing (NGS), namely, the analysis and
interpretation of genomic data obtained from patients with
cancer and other diseases and disorders
44
Providing medical information and medical advice in the
fields of retrieval, integration, correlation, analysis and
interpretation of genomic data, sequencing data and
molecular data, diseases, biomarkers, drug protocols, drug
interactions, clinical profiles, and medical and health
information, records or data and patient-specific data,
molecular test results, clinical trial data; medical
consulting services in the fields of health, medical care,
biotechnology, bioinformatics, life sciences,
pharmaceuticals and medicine; providing medical information
in the fields of health, healthcare, life sciences,
biotechnology, pharmaceuticals and pharmaceutical safety,
bioinformatics, and genetic testing for medical purposes;
medical consulting services with respect to the treatment
and diagnosis of individuals; providing medical information
on drug safety and drug compatibility in relation to therapy
and the treatment of individuals; medical consulting
services in the fields of diagnostics and patient treatment
and treatment protocols; consulting services in the field of
genomics and biological sequence processing and analysis for
medical diagnosis and treatment purposes; providing medical
information for the purposes of medical diagnosis and
treatment in the field of molecular genetics; identification
and testing of DNA samples for health care purposes; health
care services, namely, genomics and data science to provide
optimal health and disease prevention or treatment to
patients; providing health information relating to genetics
and diagnostics via the Internet; bioinformatics analysis
for medical diagnostic and personalized treatment purposes;
nucleic acid analysis and screening for medical diagnostic
and treatment purposes
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 12. November 2020 | 2020/47 Gaz | US | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 17. September 2020 | 2020/38 Gaz | JP | Ablehnung |
| 02. Juli 2020 | 2020/27 Gaz | CH | Ablehnung |
| 23. Oktober 2019 | 2019/43 Gaz | GB | Ablehnung |
| 03. Oktober 2019 | 2019/41 Gaz | CN | Ablehnung |
| 06. September 2019 | 2019/37 Gaz | US | Ablehnung |
| 09. Mai 2019 | 2019/29 Gaz | EM | Eintragung |
ID: 141480598